Mechanistic/mammalian target of rapamycin: Recent pathological aspects and inhibitors

被引:27
作者
Abdel-Maksoud, Mohammed S. [1 ]
El-Gamal, Mohammed I. [2 ,3 ]
Benhalilou, Dalia Reyane [2 ]
Ashraf, Sandy [2 ]
Mohammed, Shatha Abdulghaffar [2 ]
Oh, Chang-Hyun [4 ,5 ]
机构
[1] NRC, Pharmaceut & Drug Ind Res Div, Med & Pharmaceut Chem Dept, Giza, Egypt
[2] Univ Sharjah, Dept Med Chem, Coll Pharm, Sharjah, U Arab Emirates
[3] Univ Mansoura, Dept Med Chem, Fac Pharm, Mansoura, Egypt
[4] Korea Inst Sci & Technol, Ctr Biomat, Seoul, South Korea
[5] Univ Sci & Technol, Dept Biomol Sci, Daejeon 34113, South Korea
关键词
aging; anticancer; kinase inhibitors; mTOR; PI3K; ORALLY BIOAVAILABLE INHIBITORS; LIFE-SPAN EXTENSION; MAMMALIAN TARGET; BIOLOGICAL EVALUATION; AMINO-ACID; IN-VITRO; PYRIMIDINE-DERIVATIVES; ANTITUMOR-ACTIVITY; SIGNALING PATHWAY; KINASE INHIBITOR;
D O I
10.1002/med.21535
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The mechanistic/mammalian target of rapamycin (mTOR), also known as the mechanistic target of rapamycin, regulates many normal cell processes such as transcription, cell growth, and autophagy. Overstimulation of mTOR by its ligands, amino acids, sugars, and/or growth factors leads to physiological disorders, including cancer and neurodegenerative diseases. In this study, we reviewed the recent advances regarding the mechanism that involves mTOR in cancer, aging, and neurodegenerative diseases. The chemical and biological properties of recently reported small molecules that function as mTOR kinase inhibitors, including adenosine triphosphate-competitive inhibitors and dual mTOR/PI3K inhibitors, have also been reviewed. We focused on the reports published in the literature from 2012 to 2017.
引用
收藏
页码:631 / 664
页数:34
相关论文
共 124 条
  • [1] Design, synthesis and SAR of new-di-substituted pyridopyrimidines as ATP-competitive dual PI3Kα/mTOR inhibitors
    Al-Ashmawy, Aisha A. K.
    Ragab, Fatma A.
    Elokely, Khaled M.
    Anwar, Manal M.
    Perez-Leal, Oscar
    Rico, Mario C.
    Gordon, John
    Bichenkov, Eugeney
    Mateo, George
    Kassem, Emad M. M.
    Hegazy, Gehan H.
    Abou-Gharbia, Magid
    Childers, Wayne
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2017, 27 (14) : 3117 - 3122
  • [2] Astrocyte-neuron metabolic relationships: for better and for worse
    Allaman, Igor
    Belanger, Mireille
    Magistretti, Pierre J.
    [J]. TRENDS IN NEUROSCIENCES, 2011, 34 (02) : 76 - 87
  • [3] Astrocyte Regulation of Synaptic Behavior
    Allen, Nicola J.
    [J]. ANNUAL REVIEW OF CELL AND DEVELOPMENTAL BIOLOGY, VOL 30, 2014, 30 : 439 - 463
  • [4] Perturbations of the AKT signaling pathway in human cancer
    Altomare, DA
    Testa, JR
    [J]. ONCOGENE, 2005, 24 (50) : 7455 - 7464
  • [5] Phosphatidylinositol 3-Kinase (PI3K) and Phosphatidylinositol 3-Kinase-Related Kinase (PIKK) Inhibitors: Importance of the Morpholine Ring
    Andrs, Martin
    Korabecny, Jan
    Jun, Daniel
    Hodny, Zdenek
    Bartek, Jiri
    Kuca, Kamil
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (01) : 41 - 71
  • [6] [Anonymous], 2014, ADV GERIATR
  • [7] Rapamycin: An InhibiTOR of Aging Emerges From the Soil of Easter Island
    Apelo, Sebastian I. Arriola
    Lamming, Dudley W.
    [J]. JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES, 2016, 71 (07): : 841 - 849
  • [8] Sex- and tissue-specific changes in mTOR signaling with age in C57BL/6J mice
    Baar, Emma L.
    Carbajal, Kathryn A.
    Ong, Irene M.
    Lamming, Dudley W.
    [J]. AGING CELL, 2016, 15 (01) : 155 - 166
  • [9] Rapamycin has a deleterious effect on MIN-6 cells and rat and human islets
    Bell, E
    Cao, XP
    Moibi, JA
    Greene, SR
    Young, R
    Trucco, M
    Gao, ZY
    Matschinsky, FM
    Deng, SP
    Markman, JF
    Naji, A
    Wolf, BA
    [J]. DIABETES, 2003, 52 (11) : 2731 - 2739
  • [10] Rapamycin passes the torch: a new generation of mTOR inhibitors
    Benjamin, Don
    Colombi, Marco
    Moroni, Christoph
    Hall, Michael N.
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2011, 10 (11) : 868 - 880